Klaria Interim Report Q1 2023

Summary of the Interim Report

Net sales of 6.5 MSEK (0.0 MSEK)

Other income amounted to 0.1 MSEK (0.1 MSEK)

First quarter of 2023

- R&D costs for the period amounted to 8.6 MSEK (17.2 MSEK)

- Profit after tax amounted to -5.4 MSEK (-20.3 MSEK)

- Earnings per share for the quarter amounted to -0.06 SEK (-0.37 SEK)

- Cash flow from operating activities amounted to -9.1 MSEK (-19.8 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 13.1 MSEK (23.0 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 70.7 MSEK (72.1 MSEK)

- Klaria receives payment of 2.6 MSEK from Imbrium Therapeutics within the R&D collaboration for Adrenaline Alginate Film